drug
TECENTRIQ
updated 6mo agoby Genentech Inc
community read0 votes
🐶 often sniffed alongside
top 8- drugatezolizumab178 co-mentions · 46 sources
- tagApproval176 co-mentions · 44 sources
- companyGenentech Inc88 co-mentions · 44 sources
- drugTECENTRIQ HYBREZA20 co-mentions · 5 sources
- drug(atezolizumab + hyaluronidase (human recombinant))10 co-mentions · 5 sources
- tagOncology5 co-mentions · 2 sources
- companyDana-Farber Cancer Institute Inc1 co-mentions · 1 sources
- tagHepatology1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying TECENTRIQ
- phase3Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer
- phase3A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig
- phase2A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- phase1Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC
- phase3A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- phase2A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
- phase2A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- phase3A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
News(10)
- Roche pays Zymeworks $55M for trispecific challenger to Amgen’s ImdelltraRoche is paying Zymeworks $55 million upfront for ZW209, bagging global rights to a trispecific designed to improve on the rate and depth of responses achieved by Amgen’s Imdelltra.fiercebiotech · 27d ago
- Roche affirms sales outlook amid doubts about its futureLower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.biopharma_dive · 28d ago
- Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T assetAside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.biospace · 28d ago
- ESMO: Boehringer builds case for late-phase rival to Amgen’s ImdelltraBoehringer Ingelheim has shared data on its DLL3xCD3 T-cell engager, providing pointers to the prospects of a would-be rival to Amgen’s Imdelltra that entered phase 3 this year.fiercebiotech · 28d ago
- BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survivalWhile BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analyst…biospace · 1mo ago
- City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debutPlus news about Alchemist Capital, Newron Pharmaceuticals, Life Biosciences, Onyx Bio and Tecentriq. City Therapeutics charts $158M IPO: The RNAi startup from former Alnylam executives is looking t…endpoints · 1mo ago
- Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trialA Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.biopharma_dive · 1mo ago
- Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survivalMediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survi…fiercebiotech · 2mo ago
- 5 drugmakers chasing Merck and Moderna in the cancer vaccine raceFollowing their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…biospace · 2mo ago
- FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancerThe FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor in combination with Roche’s Tecentriq for the treatment of metastatic colorectal cancer.fiercebiotech · 2mo ago
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that